MannKind sends insulin to FDA

Share this article:

Two months after releasing Phase III data over its inhaled insulin, MannKind announced Monday it has resubmitted its FDA application for Afrezza.

The FDA rejected the drug three years ago when the manufacturer submitted data that predated an inhaler change.

Clearing the FDA would put Afrezza on previously trod ground. Pfizer abandoned its inhaled insulin Exubera following poor sales. Novo and Lilly have also left inhaled insulin efforts in the dust.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.